ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS

Project Information

UNITE4TB

Grant agreement ID: 101007873

DOI

10.3030/101007873

EC signature date 29 June 2021

Start date 1 June 2021

End date 31 May 2028

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 185 000 000,00

EU contribution

€ 92 500 000,00

Coordinated by

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Netherlands

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (15)

Report of kick-off meeting

Report of kickoff meeting

Midterm recruitment report for phase 2B/C

Midterm recruitment report for phase 2B/CNote: this is a summary report for all phase 2B/C studies to be performed

Target product profile for stage-specific biomarkers - submitted to WHO and EMA

Target product profile for stage-specific biomarkers – submitted to WHO and EMA

Report of third annual consortium meeting
Communication and dissemination plan
Report of second annual consortium meeting
Annual report on status of posting results for phase 2B/C (1)
Establish CAG
Establish SAB and RAB
Annual report on status of posting results for phase 2A (1)
DAT training module developed
Attendance at key regional stakeholder events to discuss findings (1)
Report of first annual consortium meeting
Establish EAB
Code for pharmacodynamic models applicable phase 2A and 2B/C data (1)

Code for pharmacodynamic models applicable phase 2A and 2B/C data (1)

Websites, patent fillings, videos etc. (2)

Dissemination of educational materials through CME-webinars (1)
Visual identity and communication toolkit, including project website

Visual identity and communication toolkit including project website

Other (3)

Inaugural meeting with communication professionals of the partners in the consortium
Establish Young Investigators Group
Seminars for healthcare workers (1)

Publications

Peer reviewed articles (17)

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Author(s): Keutzer L, You H, Farnoud A, Nyberg J, Wicha SG, Maher-Edwards G, Vlasakakis G, Moghaddam GK, Svensson EM, Menden MP, Simonsson USH, On Behalf Of The UNITE4TB Consortium
Published in: Pharmaceutics, 2022, ISSN 1999-4923
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14081530

Candidate anti-tuberculosis medicines and regimens under clinical evaluation

Author(s): Michael Hoelscher, David Barros-Aguirre, Masoud Dara, Norbert Heinrich, Eugene Sun, Christoph Lange, Simon Tiberi, Charles Wells
Published in: Clinical Microbiology and Infection, Issue 30, 2024, Page(s) 1131-1138, ISSN 1198-743X
Publisher: Blackwell Publishing Inc.
DOI: 10.1016/j.cmi.2024.06.016

A flexible multi‐metric Bayesian framework for decision‐making in Phase II multi‐arm multi‐stage studies

Author(s): Suzanne M. Dufault; Angela M. Crook; Katie Rolfe; Patrick P. J. Phillips
Published in: Statistics in Medicine , 43 (3) pp. 501-513. (2024), Issue 17, 2024, Page(s) 501-513, ISSN 0277-6715
Publisher: John Wiley & Sons Inc.
DOI: 10.1002/sim.9961

Treatment-shortening regimens for tuberculosis: updates and future priorities

Author(s): Francesca Saluzzo, Victor Abiola Adepoju, Raquel Duarte, Christoph Lange, Patrick P.J. Phillips
Published in: Breathe, Issue 19 (3), October, 2023, ISSN 1810-6838
Publisher: European Respiratory Society
DOI: 10.1183/20734735.0028-2023

Tuberculosis: current challenges and beyond

Author(s): Raquel Villar-Hernández, Arash Ghodousi, Olha Konstantynovska, Raquel Duarte, Christoph Lange, Mario Raviglione on behalf of the UNITE4TB Consortium
Published in: Breath, 2023, ISSN 2073-4735
Publisher: European Respiratory Society
DOI: 10.1183/20734735.0166-2022

Towards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis

Author(s): Simone Villa, Pierpaolo de Colombani, Lucia Dall’Olio, Giuliano Gargioni, Mario Raviglione
Published in: BMJ Global Health, Issue 2024;9: e014630, 2024, Page(s) 1-9, ISSN 2059-7908
Publisher: BMJ Journals
DOI: 10.1136/bmjgh-2023-014630

Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies

Author(s): Heyckendorf J, Georghiou SB, Frahm N, Heinrich N, Kontsevaya I, Reimann M, Holtzman D, Imperial M, Cirillo DM, Gillespie SH, Ruhwald M, Consortium UNITE4TB
Published in: Clinical Microbiology Reviews, Issue 21 March 2022, 2022, Page(s) n/a, ISSN 1098-6618
Publisher: American Society for Microbiology
DOI: 10.1128/cmr.00227-21

Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles 

Author(s): Stephen H Gillespie , Andrew R DiNardo, Sophia B Georghiou, Wilber Sabiiti , Mikashmi Kohli, Ursula Panzner , Irina Kontsevaya6, Norbert Hittel, Lieven J Stuyver, Jia Bin Tan, Reinout van Crevel, Christoph Lange, Thuong Nguyen Thuy Thuong, Jan Heyckendorf, Morten Ruhwald, Norbert Heinrich
Published in: Lancet Microbe, 2024, Page(s) 1-11, ISSN 2666-5247
Publisher: Elsevier ltd.
DOI: 10.1016/s2666-5247(24)00085-5

Advances in tuberculosis biomarkers: unravelling risk factors, active disease and treatment success

Author(s): Jodie A. Schildkraut, Niklas Köhler, Christoph Lange, Raquel Duarte, Stephen H. Gillespie
Published in: Breathe, Issue 20, 2024, Page(s) 240003, ISSN 1810-6838
Publisher: European Respiratory Society
DOI: 10.1183/20734735.0003-2024

The importance of getting the dose right in the treatment of tuberculosis

Author(s): Andrii Dudnyk, Wandini Lutchmun, Raquel Duarte, Christoph Lange, Elin M. Svensson
Published in: Breathe, Issue 21, 2025, Page(s) 240177, ISSN 1810-6838
Publisher: European Respiratory Society
DOI: 10.1183/20734735.0177-2024

Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

Author(s): Yu‐Jou Lin, Louvina E. van der Laan, Mats O. Karlsson, Anthony J. Garcia‐Prats, Anneke C. Hesseling, Elin M. Svensson
Published in: Clinical Pharmacology & Therapeutics, Issue 117, 2025, Page(s) 1292-1302, ISSN 0009-9236
Publisher: Nature Publishing Group
DOI: 10.1002/cpt.3536

Interoccasion variability in population pharmacokinetic models: identifiability, influence, interdependencies and derived study design recommendations

Author(s): Emily Behrens, Sebastian G. Wicha
Published in: Journal of Pharmacokinetics and Pharmacodynamics, Issue 52, 2025, ISSN 1567-567X
Publisher: Kluwer Academic/Plenum Publishers
DOI: 10.1007/s10928-025-09966-7

The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships

Author(s): Josepine Fernow, Marie Olliver, William Couet, Sophie Lagrange, Meindert H. Lamers, Ole F. Olesen, Kristina Orrling, Michel Pieren, Derek J. Sloan, Juan José Vaquero, Timothy J. Miles, Anders Karlén
Published in: Nature Reviews Drug Discovery, Issue 24, 2025, Page(s) 1-2, ISSN 1474-1776
Publisher: Nature Publishing Group
DOI: 10.1038/d41573-024-00138-9

Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries

Author(s): Anca Vasiliu, Antonia Morita Iswari Saktiawati, Raquel Duarte, Christoph Lange, Daniela Maria Cirillo on behalf of the UNITE4TB Consortium
Published in: Breath, 2023, ISSN 2073-4735
Publisher: European Respiratory Society
DOI: 10.1183/20734735.0226-2022

Artificial intelligence in tuberculosis: a new ally in disease control

Author(s): Mairi McClean, Traian Constantin Panciu, Christoph Lange, Raquel Duarte, Fabian Theis
Published in: Breathe, Issue 20, 2024, Page(s) 240056, ISSN 1810-6838
Publisher: European Respiratory Society
DOI: 10.1183/20734735.0056-2024

Rolling out new anti-tuberculosis drugs without diagnostic capacity

Author(s): Tara Ness, Le Hong Van, Ilze Petermane, Raquel Duarte, Christoph Lange, Dick Menzies, Daniela Maria Cirillo
Published in: Breathe, Issue 19(2), July, 2023, ISSN 1810-6838
Publisher: European Respiratory Society
DOI: 10.1183/20734735.0084-2023

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Author(s): Mockeliunas L, Faraj A, van Wijk RC, Upton CM, van den Hoogen G, Diacon AH, Simonsson USH
Published in: Front. Pharmacol., 2023, ISSN 1663-9812
Publisher: Frontiers Media S.A.
DOI: 10.3389/fphar.2023.1150243

Non-peer reviewed articles (1)

UNITE4TB: a new consortium for clinical drug and regimen development for TB

Author(s): Boeree, M. J.; Lange, C.; Thwaites, G; Paton, N ; de Vrueh, R.; Barros, D.; Hoelscher, M.; on behalf of the UNITE4TB Consortium
Published in: International Union Against Tuberculosis and Lung Disease, Issue Volume 25, Number 11, 1 November 2021, 2021, Page(s) 886-889, ISSN 1027-3719
Publisher: International Union Against Tuberculosis And Lung Disease/Union Internationale Contre la Tuberculose et les Maladies Respiratories
DOI: 10.5588/ijtld.21.0515